Rutgers University in Newark, N.J., and president of BLCMD Associates LLC in Chapel Hill, N.C., which offers consulting services in drug safety. ... Indeed, in the November 2011 Drug Safety, researchers published a study examining the prescription data
It's also recommended that clinicians discontinue the drug in patients with symptoms of liver injury. ... A drug safety communication about the risk of name confusion between ado-trastuzumab emtansine (Kadcyla) and trastuzumab (Herceptin).
A warning about drug interactions between boceprevir (Victrelis) and ritonavir-boosted HIV protease inhibitor drugs. ... However, the FDA continues to believe that the cardiovascular benefits of statins outweigh these small increased risks, according to
A drug safety communication that hepatitis C medicines have led to rare cases of worsening liver function or liver failure in some patients. ... The drug was originally approved in 2014 to treat adults with idiopathic pulmonary fibrosis.